Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
A distinct "side population" of cells with high drug efflux capacity in human tumor cells.
- C. Hirschmann-Jax, A. Foster, +5 authors M. Brenner
- Biology, Medicine
- Proceedings of the National Academy of Sciences…
- 28 September 2004
A distinct SP was found in neuroblastoma cells from 15 of 23 patients and showed evidence for asymmetric division, generating both SP and non-SP progeny, suggesting that this phenotype defines a class of cancer stem cells with inherently high resistance to chemotherapeutic agents that should be targeted during the treatment of malignant disease. Expand
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
- B. Savoldo, C. Ramos, +13 authors G. Dotti
- Medicine, Biology
- The Journal of clinical investigation
- 2 May 2011
The results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies. Expand
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
Polyclonal donor-derived T-cell lines specific for EBV proteins can be used safely to prevent EBV-related immunoblastic lymphoma after allogeneic marrow transplantation and may also be effective in the treatment of established disease. Expand
Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
Improvements in total body bone mineral content and growth velocity were associated with increases in growth velocity and reduced frequencies of bone fracture, indicating the feasibility of allogeneic bone marrow transplantation in the treatment of osteogenesis imperfecta and perhaps other mesenchymal stem cell disorders as well. Expand
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
EBV-specific donor-type T-cell lines seem to offer safe and effective therapy for control of EBV-associated lymphoproliferation in patients with EBV reactivation after bone-marrow transplantation. Expand
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
It is shown in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity. Expand
Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes
These findings support wider use of antigen–specific CTLs in adoptive immunotherapy and restore cellular immune responses against EBV, but also established populations of CTL precursors that could respond to in vivo or ex vivo challenge with the virus for as long as 18 months. Expand
Inducible apoptosis as a safety switch for adoptive cell therapy.
- A. Di Stasi, Siok-Keen Tey, +17 authors M. Brenner
- The New England journal of medicine
- 2 November 2011
The inducible T-cell safety switch based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization may increase the safety of cellular therapies and expand their clinical applications. Expand
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
It is shown that GD2-CAR T cells can induce complete tumor responses in patients with active neuroblastoma; these CAR T cells may have extended, low-level persistence in patients, and such persistence was associated with longer survival. Expand
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
- M. Pule, K. Straathof, G. Dotti, H. Heslop, C. Rooney, M. Brenner
- Biology, Medicine
- Molecular therapy : the journal of the American…
- 1 November 2005
It is hypothesized that the CD28-OX40-CD3zeta tripartite cytoplasmic domain will provide a full complement of activation, proliferation, and survival signals for enhanced anti-tumor activity. Expand